RMC-9805 looks more efficacious, and less toxic, than Astellas’s G12D degrader in pancreatic cancer.

There’s little to distinguish the two HIF2α inhibitors in kidney cancer.

The company reckons it’s got what it takes to hit the right member of the FGFR family.

AKY-1189 could be used in Padcev-relapsed patients, and in cancers beyond bladder.

ZL-1310 looks better than other DLL3-targeting agents, but two thirds of responses are so far unconfirmed.

The group will present the first clinical data on its KRAS G12D-selective project RMC-9805.

Aktis scores a plenary, as do Tyra’s FGFR3 inhibitor and Arcus’s HIF-2α contender.

Approval decisions loom for Opdivo and Lumakras, and earnings season starts again.